MiniPDX® Application in Drug R&D and and Correlation with PDX

The MiniPDX® test can provide drug sensitivity results in as little as 7 days vs. the 4-6 months needed for traditional PDX results. Given the time savings of MiniPDX® vs traditional PDX, it is natural to ask how results correlate between the two model types. In a published study, LIDE used 26 PDX models generated from patient tumor samples, including 14 gastric cancers, 10 lung cancers and 2 pancreatic cancers to demonstrate that drug responses in the PDX tumor graft assays correlated well with those in the corresponding MiniPDX assays. The positive predictive value of MiniPDX was 92% vs. PDX, and the negative predictive value was 81% with a sensitivity of 80% and a specificity of 93%.


Fig. Comparing efficacy results of drug S1 in PDX assays vs. equivalent MiniPDX assays.

Fig. Comparing efficacy results of drug S1 in PDX assays vs. equivalent MiniPDX assays. 

PDX is well studied and shown to be 89% correlated with clinical result. Taken together with MiniPDX® results, this means MiniPDX® is 82% correlated with clinical results, by calculation. In China, LIDE has verified this in the clinical setting, with over 2600 treated cases at over 80% effectiveness.

Several papers have been published supporting MiniPDX®:

Download all of our papers here.

Application in Drug R&D
The high correlation between drug responses of paired MiniPDX® and PDX tumor graft assay, as well as translational data, suggest that MiniPDX® assay can be an effective pre-clinical testing tool in drug R&D.

Applications of MiniPDX in Drug R&D:

Drug Development Phase MiniPDX Benefit
Lead Optimization Fast screening of candidate molecules to identify which is best for further resource investment
Lead Validation Post in-vitro studies, MiniPDX screens using PDX cells can identify the best PDX model for further in-vivo validation
Pre-clinical Development MiniPDX Mouse Trial using fresh tumor samples can identify or verify potential clinical indications
Clinical Development MiniPDX + OMICS analysis can reveal biomarkers for patient stratification and trial recruitment strategy

In addition, by combining MiniPDX® functional testing with proprietary LIDE OncoVee™ K-cell technology , drug development companies can also identify biomarkers that will be useful in patient stratification for clinical trials. LIDE calls this combined (MiniPDX® trial + omics analysis) approach “Functional Diagnosis” and we believe it is the future of drug R&D. Review a case study and learn more about Functional Diagnosis here.